|
| Frontiers in Inflammation Pharmacology |
|
| Published on 13 March 2013 |
| Inhibitory Effects of Sigma-2 Receptor Agonists on T Lymphocyte Activation |
| Miguel A. Iñiguez, Carmen Punzón, Raquel Nieto, Javier Burgueño, José M. Vela, and Manuel Fresno |
| Published on 22 March 2013 |
| Assessment of expenditure control and prescriptive appropriateness of biological drugs in autoimmune diseases and chronic inflammatory bowel disease |
| Maurizio Capuozzo, Eduardo Nava, Stefania Cascone, Claudia Cinque, Roberta Marra, Alessandro Ottaiano, Corinne Scognamiglio, and Emilia Palumbo |
|
| Frontiers in Neuropharmacology |
|
| Published on 6 March 2013 |
| Prediction of Selective Serotonin Reuptake Inhibitor Response Using Diffusion-Weighted MRI |
| Christine DeLorenzo, Lauren Delaparte, Binod Thapa-Chhetry, Jeffrey M. Miller, J. John Mann, and Ramin V. Parsey |
| Published on 13 March 2013 |
| Selective Pharmacological Modulation of Pyramidal Neurons and Interneurons in the CA1 Region of the Rat Hippocampus |
| Marzia Martina, Tanya Comas, and Geoffrey A. R. Mealing |
| Published on 26 March 2013 |
| Limbic system associated membrane protein as a potential target for neuropsychiatric disorders |
| Jürgen Innos, Kati Koido, Mari-Anne Philips, and Eero Vasar |
|
|
|
| Frontiers in Pharmacology of Anti-Cancer Drugs |
|
| Published on 6 March 2013 |
| Extracellular Vesicles – Biomarkers and Effectors of the Cellular Interactome in Cancer |
| Janusz Rak |
| Published on 11 March 2013 |
| Physician Recruitment of Patients to Non-Therapeutic Oncology Clinical Trials: Ethics Revisited |
| Lee Black, Gerald Batist, Denise Avard, Caroline Rousseau, Zuanel Diaz, and Bartha Maria Knoppers |
| Published on 12 March 2013 |
| Cardiotoxicity of Cancer Therapeutics: Current Issues in Screening, Prevention, and Therapy |
| Richard J. Sheppard, Jenna Berger, and Igal A. Sebag |
| Published on 14 March 2013 |
| Mechanisms and insights into drug resistance in cancer |
| Hiba Zahreddine and Katherine L. B. Borden |
| Published on 22 March 2013 |
| Targeting the insulin-like growth factor-1 receptor in human cancer |
| Alexandre Arcaro |
| Published on 22 March 2013 |
| Tumor P-Glycoprotein Correlates with Efficacy of PF-3758309 in in vitro and in vivo Models of Colorectal Cancer |
| Erica Lynn Bradshaw-Pierce, Todd M. Pitts, Aik-Choon Tan, Kelly McPhillips, Mark West, Daniel L. Gustafson, Charles Halsey, Leslie Nguyen, Nathan V. Lee, Julie L. C. Kan, Brion William Murray, and S. Gail Eckhardt |
| Published on 28 March 2013 |
| Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models |
| Todd M. Pitts, Gillian N. Kulikowski, Aik-Choon Tan, Brion W. Murray, John J. Arcaroli, John J. Tentler, Anna Spreafico, Heather M. Selby, Maria I. Kachaeva, Kelly L. McPhillips, Blair C. Britt, Erica L. Bradshaw-Pierce, Wells A. Messersmith, Marileila Varella-Garcia, and S. Gail Eckhardt |
| Published on 28 March 2013 |
| COX-2 in cancer: Gordian knot or Achilles heel? |
| Ioannis Stasinopoulos, Tariq Shah, Marie-France Penet, Balaji Krishnamachary, and Zaver M. Bhujwalla |
|
